874-77-1

• 常用中文名：4-甲基-1-哌嗪乙腈
• 常用英文名：1-(4-METHYLPIPERAZINE)ACETONITRILE
• CAS号：874-77-1
• 分子式：C₇H₁₃N₃
• 分子量：139.19800
• 发布时间：2018-10-03 10:17:34
• 更新时间：2024-02-03 12:20:19

名称

• 中文名: 1-(4-甲基哌嗪)乙腈
• 英文名: 2-(4-methylpiperazin-1-yl)acetonitrile
• 中文别名: 4-甲基-1-哌嗪乙腈
• 英文别名: 1-Methyl-4-cyanmethyl-piperazin; 4-Methyl-piperazinyl-(1)-acetonitril; N-Methyl-N'-cyanomethylpiperazin; (4-methylpiperazin-1-yl)acetonitrile; BB_SC-8593; 4-Methyl-1-piperazineacetonitrile; (4-Methyl-piperazino)-acetonitril; 1-(4-Methylpiperazine)acetonitrile

物化性质

• 密度: 0.998g/cm3
• 沸点: 230.152ºC at 760 mmHg
• 分子式: C₇H₁₃N₃
• 分子量: 139.19800
• 闪点: 89.486ºC
• 精确质量: 139.11100
• PSA: 30.27000
• 折射率: 1.478
• 储存条件: 室温

安全

• 海关编码: 2933599090

合成路线

109-01-3 107-14-2 ~10% 874-77-1

文献：NEUROPORE THERAPIES, INC.; WRASIDLO, Wolfgang Patent: WO2013/148365 A1, 2013 ; Location in patent: Paragraph 0085 ;

109-01-3 590-17-0 ~55% 874-77-1

文献：Palmer, James T.; Bryant, Clifford; Wang, Dan-Xiong; Davis, Dana E.; Setti, Eduardo L.; Rydzewski, Robert M.; Venkatraman, Shankar; Tian, Zong-Qiang; Burrill, Leland C.; Mendonca, Rohan V.; Springman, Eric; McCarter, John; Chung, Tobee; Cheung, Harry; Janc, James W.; McGrath, Mary; Somoza, John R.; Enriquez, Philip; Yu, Z. Walter; Strickley, Robert M.; Liu, Liang; Venuti, Michael C.; Percival, M. David; Falgueyret, Jean-Pierre; Prasit, Peppi; Oballa, Renata; Riendeau, Denis; Young, Robert N.; Wesolowski, Gregg; Rodan, Sevgi B.; Johnson, Colena; Kimmel, Donald B.; Rodan, Gideon Journal of Medicinal Chemistry, 2005 , vol. 48, # 24 p. 7520 - 7534

143-33-9 19212-84-1 ~% 874-77-1

文献：European Journal of Medicinal Chemistry, , vol. 42, # 4 p. 471 - 476

109-01-3 ~% 874-77-1

文献：European Journal of Medicinal Chemistry, , vol. 42, # 4 p. 471 - 476

上下游产品

上游产品  5
109-01-3 107-14-2 590-17-0 143-33-9
19212-84-1
下游产品  2
934-98-5 164926-91-4

海关

海关编码	2933599090
中文概述	2933599090. 其他结构上有嘧啶环的化合物(包括其他结构上有哌嗪环的化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%
申报要素	品名, 成分含量, 用途, 乌洛托品请注明外观, 6－己内酰胺请注明外观, 签约日期
Summary	2933599090. other compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%